Bolt Biotherapeutics Inc (BOLT) 13F Holders & Ownership Data (24 Funds, Q2 2026)

BOLT ranks #7984 out of 37701 tracked stocks by institutional interest, inside the more closely watched half of our coverage.

BOLT is a disclosed holding of Jim Simons (Renaissance Technologies), one of the tracked superinvestors on AlphaSMO — it makes up 0.0% of that fund's own 13F portfolio.

24 institutions disclose a position in BOLT, but none treat it as a major bet — even T3 Companies, LLC, its most concentrated holder, allocates just 0.2% of its own portfolio to it.

T3 Companies, LLC has trimmed its BOLT position for two straight quarters, cutting it by $13.7K while still holding $139.8K.

BOLT reported a net loss of $28.7M over the trailing twelve months.

• Not yet profitable — net loss of $28.7M over the trailing twelve months
• Revenue grew 12.8% year over year
• Net income improved year over year, from -$50.7M to -$28.7M
• Operating cash flow was negative, using $39.9M in cash
• Current ratio of 3.59x — enough short-term assets to cover short-term liabilities
• Liabilities run 1.14x equity — within a conventional range